Bone Health Clinic Pharmaceutical Management Survey

Section 1 – Practice Profile

1. What best describes your organization?
   ☐ Independent orthopedic practice
   ☐ Multi-specialty group
   ☐ Hospital-owned practice
   ☐ Academic medical center
   ☐ Other (please specify): __________

2. Approximate number of osteoporosis or bone health patients managed annually:
   ☐ <100 ☐ 100–499 ☐ 500–999 ☐ 1,000+

3. Does your practice currently provide in-office osteoporosis injection therapy (e.g., Prolia, Evenity)?
   ☐ Yes ☐ No ☐ Planning to start within 12 months

4. Who manages drug purchasing and inventory for your practice?
   ☐ Physician-owner(s)
   ☐ Practice administrator
   ☐ Pharmacy or infusion manager
   ☐ Hospital or corporate supply chain
   ☐ Other: __________

Section 2 – Current Model: Buy-and-Bill

1. Do you currently purchase osteoporosis biologics under a buy-and-bill model?
   ☐ Yes ☐ No

2. How significant is buy-and-bill inventory cost as a financial burden to your practice?
   Scale: 1 = Minimal → 5 = Severe burden
   ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5

3. What challenges do you face under the buy-and-bill model? (Select all that apply)
   ☐ Upfront cash flow / working capital requirements
   ☐ Reimbursement delays or denials
   ☐ Expired / wasted inventory
   ☐ Administrative complexity
   ☐ Payer mix variability
   ☐ None / minimal issues
   ☐ Other: __________

4. Have reimbursement levels for Prolia or Evenity changed your willingness to continue buy-and-bill?
   ☐ No impact
   ☐ Somewhat less willing
   ☐ Much less willing
   ☐ Considering discontinuation

Section 3 – Awareness & Perception of Consignment

1. How familiar are you with the concept of consigned drug inventory?
   ☐ Not familiar ☐ Somewhat familiar ☐ Very familiar

2. Have you ever used a consignment model in your practice (for any medication or implant)?
   ☐ Yes ☐ No ☐ Not sure

3. If yes, in what context?
   ☐ Orthopedic implants ☐ Oncology biologics ☐ Other: __________

4. What potential advantages do you see in a consignment model for bone health drugs? (Select up to 3)
   ☐ Eliminates upfront inventory costs
   ☐ Reduces financial risk
   ☐ Enables more consistent patient access
   ☐ Simplifies purchasing and cash flow
   ☐ Easier to adopt biosimilars
   ☐ Other: __________

5. What concerns would you have about using a consignment model? (Select all that apply)
   ☐ Legal/regulatory compliance (anti-kickback, etc.)
   ☐ Contract complexity
   ☐ Loss of control over inventory
   ☐ Operational logistics with 3PL/distributor
   ☐ Data reporting requirements
   ☐ Other: __________

Section 4 – Adoption Interest

1. If a compliant consignment solution were available today, how interested would your practice be in participating?
   ☐ Very interested ☐ Moderately interested ☐ Unsure ☐ Not interested

2. Which product transition would be most relevant for your practice?
   ☐ Prolia → Denosumab biosimilar (when available)
   ☐ Evenity (Romosozumab)
   ☐ Other injectable osteoporosis agents

3. What support would your practice need to adopt a consignment model? (Select all that apply)
   ☐ Legal and compliance review
   ☐ Integration with existing billing workflows
   ☐ Training for staff
   ☐ Data/reporting automation
   ☐ 3PL logistics coordination
   ☐ Financial modeling or revenue impact analysis

4. Would you be willing to participate in a pilot program testing a consignment model for bone health biologics?
   ☐ Yes ☐ Possibly, with more information ☐ No

5. If yes or possibly, please provide a contact person for follow-up:
   Name: __________ Title: __________ Email: __________ Phone: __________

Section 5 – Open Feedback

1. In your own words, what would make a consignment model appealing or unattractive to your practice?
   (Open-ended text field)

2. Do you have any additional comments or suggestions regarding how a consignment model could support bone health service growth?
   (Open-ended text field)